Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV). The company is also developing STimulator of INterferon Genes agonist product candidate, including SB 11285, an immunotherapeutic agent for the potential treatment of selected cancers. It has a collaboration agreement with Gilead Sciences, Inc. for conducting a Phase II clinical trial examining the co-administration of inarigivir and Vemlidy in patients infected with chronic HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone508-473-5993
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$350,000.00
Profitability
Miscellaneous
Employees29
Next Earnings Date4/26/2019 (Estimated)
OptionableNot Optionable
Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions
What is Spring Bank Pharmaceuticals' stock symbol?
Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."
How were Spring Bank Pharmaceuticals' earnings last quarter?
Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) posted its quarterly earnings data on Monday, March, 11th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.50) by $0.17. View Spring Bank Pharmaceuticals' Earnings History.
When is Spring Bank Pharmaceuticals' next earnings date?
What price target have analysts set for SBPH?
4 analysts have issued twelve-month price objectives for Spring Bank Pharmaceuticals' shares. Their predictions range from $25.00 to $29.00. On average, they expect Spring Bank Pharmaceuticals' share price to reach $26.75 in the next year. This suggests a possible upside of 275.2% from the stock's current price. View Analyst Price Targets for Spring Bank Pharmaceuticals.
What is the consensus analysts' recommendation for Spring Bank Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spring Bank Pharmaceuticals.
Has Spring Bank Pharmaceuticals been receiving favorable news coverage?
News stories about SBPH stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Spring Bank Pharmaceuticals earned a daily sentiment score of 2.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the company's share price in the next few days.
Who are some of Spring Bank Pharmaceuticals' key competitors?
Some companies that are related to Spring Bank Pharmaceuticals include BioSpecifics Technologies (BSTC), Corium International (CORI), Corbus Pharmaceuticals (CRBP), Collegium Pharmaceutical (COLL), CytomX Therapeutics (CTMX), Cytokinetics (CYTK), ProQR Therapeutics (PRQR), Kalvista Pharmaceuticals (KALV), NuCana (NCNA), Five Prime Therapeutics (FPRX), Prothena (PRTA), Cyclerion Therapeutics (CYCN), Assembly Biosciences (ASMB), INDIVIOR PLC/S (INVVY) and Dynavax Technologies (DVAX).
What other stocks do shareholders of Spring Bank Pharmaceuticals own?
Who are Spring Bank Pharmaceuticals' key executives?
Spring Bank Pharmaceuticals' management team includes the folowing people:
- Mr. Martin J. Driscoll, Pres, CEO & Director (Age 60)
- Dr. Radhakrishna P. Iyer, Co-Founder, Chief Scientific Officer & Director (Age 69)
- Dr. Nezam H. Afdhal, Chief Medical Officer (Age 62)
- Mr. Jonathan P. Freve CPA, CFO & Treasurer (Age 41)
- Mr. Donald Mitchell MBA, VP of Operations & Corp. Devel.
When did Spring Bank Pharmaceuticals IPO?
(SBPH) raised $14 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 1,100,000 shares at $12.00-$14.00 per share. Dawson James Securities served as the underwriter for the IPO.
How do I buy shares of Spring Bank Pharmaceuticals?
Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spring Bank Pharmaceuticals' stock price today?
One share of SBPH stock can currently be purchased for approximately $7.13.
How big of a company is Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals has a market capitalization of $117.20 million and generates $350,000.00 in revenue each year. The company earns $-22,850,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Spring Bank Pharmaceuticals employs 29 workers across the globe.
What is Spring Bank Pharmaceuticals' official website?
How can I contact Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals' mailing address is 35 Parkwood Drive, Hopkinton MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]
MarketBeat Community Rating for Spring Bank Pharmaceuticals (NASDAQ SBPH)
MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharmaceuticals and other stocks. Vote "Outperform" if you believe SBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
